Abstract: An improved process for the production of 1-dialkyl-amino-ethyl-6-aryl-4H-s-triazolo[4,3-a][1,4]benzodiazepines of the formula II: ##STR1## wherein R.sub.1 is alkyl of 1 to 3 carbon atoms, inclusive; wherein R.sub.2 is hydrogen, methyl or phenyl; wherein the ring A is unsubstituted, or monosubstituted with fluoro, chloro, bromo, nitro, trifluoromethyl or methylthio; and wherein Ar is phenyl; o-chlorophenyl; o-fluorophenyl; 2,6-difluorophenyl or 2-pyridyl, is carried out by reacting a compound of the Formula I: ##STR2## wherein ring A, Ar and R.sub.2 are defined as above, with a dialkylmethyleneammonium salt in the presence of a reactive carboxylic acylating agent.The compounds of Formula II (R.sub.2 .dbd.H) are known compounds (Belgian Pat. No. 782,84g) which have sedative-tranquilizing as well as pronounced anti-depressant activity, suitable for the treatment of anxieties and depressions in mammals, including man.

Abstract: Compounds of the formula ##STR1## wherein R.sub.o is hydrogen or alkyl of 1-3 carbon atoms, inclusive; wherein R.sub.1 is hydrogen, fluoro, chloro, bromo, nitro, trifluoromethyl or alkylthio in which the alkyl moiety is of 1 to 3 carbon atoms, inclusive; and wherein R.sub.2 is phenyl, o-chlorophenyl, o-fluorophenyl, 2,6-difluorophenyl or 2-pyridyl, or the pharmaceutically acceptable acid addition salts thereof. The compounds are useful as sedatives, antianxiety agents, antidepressants, anticonvulsives and muscle-relaxing agents.

Abstract: Compounds of the formula II: ##STR1## wherein R is cyclopropyl, cyclopropylmethyl, or allyl; wherein R', R", and R.sub.1 are hydrogen or alkyl of 1 to 3 carbon atoms inclusive; and wherein R.sub.2, R.sub.3, and R.sub.4 are hydrogen, alkyl as defined above, fluoro, chloro, bromo, nitro, trifluoromethyl, or alkylthio in which alkyl is defined as above, are prepared by reacting a compound of the formula I. ##STR2## wherein R", R.sub.1, R.sub.2, R.sub.3, and R.sub.4 are defined as above, and wherein X is chlorine or bromine, with an amine of the formula ##STR3## wherein R and R' are defined as above. The compounds of formula II and the pharmacologically acceptable acid salts thereof have tranquilizing, sedative, antianxiety, and anticonvulsant activity and can be used in animals and birds.

Abstract: 6-(o-halophenyl)-1-methyl-4H-s-triazolo[4,3-a][1,4]-benzodiazepines of the following formula: ##STR1## wherein the substituent "Hal" is either of the halogens having an atomic number up to 35, inclusive, i.e., fluoro, chloro or bromo, and their pharmacologically acceptable acid addition salts which are especially useful as muscle relaxing and anxiolylic agents.

Abstract: Compounds of the formula: ##STR1## wherein R is hydrogen, methyl, or ethyl; wherein R' and R" are hydrogen, alkyl of 1 to 3 carbon atoms, inclusive, wherein R.sub.1 is hydrogen or methyl defined as above; wherein R.sub.2, R.sub.3, R.sub.4, and R.sub.5 are selected from the group consisting of hydrogen, alkyl defined as above, halogen, nitro, trifluoromethyl, and alkoxy and alkylthio, in which the carbon chain moieties are of 1 to 3 carbon atoms, inclusive; and wherein the 5 to 6 nitrogen-carbon linkage is selected from the group consisting of double bonds and single bonds, are produced by a variety of multistep processes.The new compounds of formula X above and the pharmacologically acceptable acid addition salts thereof have oral and parenteral sedative and tranquilizing activity, and anti-depressant activity and can be employed for tranquilizing mammals as well as combating anxiety and depressions.

Abstract: Compounds of the formula: ##STR1## wherein R'o and R"o are hydrogen or alkyl of 1 to 3 carbon atoms, inclusive; R.sub.1 is hydrogen, fluoro, chloro, bromo, nitro, trifluoromethyl, or alkylthio in which the alkyl moiety is of 1 to 3 carbon atoms, inclusive; R.sub.2 is phenyl, o-chlorophenyl, 0-fluorophenyl, 2,6-difluorophenyl and 2-pyridyl are prepared by multistep reactions from compounds of formula I: ##STR2## wherein R.sub.1 and R.sub.2 are defined as above and X is chlorine or bromine.Compounds of formula III, intermediates in the preparation thereof, Schiff's bases of compounds IIIA (III in which R'o and R"o are hydrogen), and the pharmacologically acceptable acid addition salts are useful in birds and mammals, including man, as sedatives, antianxiety, antidepressant, anticonvulsive, and muscular relaxing agents.

Abstract: Intermediates of the formula IV: ##STR1## wherein R is selected from the group consisting of hydrogen and alkyl of 1 to 3 carbon atoms, inclusive; and wherein R.sub.2, R.sub.3, and R.sub.4 are selected from the group consisting of hydrogen, fluoro, chloro, bromo, nitro, and trifluoromethyl are produced by a multistep synthesis. The final compounds are tranquilizers and sedatives and can be used in mammals, including man, and in birds.

Abstract: Intermediates of the formula VI: ##STR1## wherein R is hydrogen or alkyl of 1 to 3 carbon atoms, inclusive, wherein R.sub.2 is hydrogen, fluoro, or chloro; wherein R.sub.3 is hydrogen or fluoro with the proviso that R.sub.3 is not fluoro, if R.sub.2 is chloro; wherein R.sub.4 is hydrogen, fluoro, chloro, bromo, trifluoromethyl, or nitro; and wherein X is chloro, bromo, or iodo, are produced by a multistep process. The compounds VI serve as intermediates for final compounds which are tranquilizers and sedatives and as such useful in mammals and birds.

Abstract: 1-Piperazino-6-(2-pyridyl)-4H-s-triazolo[4,3-a][1,4]benzodiazepines of the formula II: ##SPC1##wherein R is hydrogen, alkyl of 1 to 3 carbon atoms, inclusive, or .beta.-hydroxyethyl; wherein R.sub.1 is hydrogen or alkyl defined as above; and wherein R.sub.2 and R.sub.3 are hydrogen, alkyl as defined above, fluoro, chloro, bromo, nitro or trifluoromethyl, are obtained by reacting a compound of the formula I: ##SPC2##wherein R.sub.1, R.sub.2, and R.sub.3 are defined as above and wherein X is chloro or bromo with a piperazine of the formula: ##SPC3##Wherein R is defined as above.The compounds of the formula II and their pharmacologically acceptable acid addition salts thereof, have tranquilizing, sedative and anti-depressant effects, and are useful for suppression of anxiety and depression in mammals and birds.

Abstract: Pharmaceutical compositions comprising, in unit dosage form, from about 0.5 mg. to about 100 mg. of a compound of the formula ##SPC1##Wherein R and R' are hydrogen, methyl or ethyl, R.sub.1 is hydrogen or lower alkyl of 1 through 3 carbon atoms, R.sub.2 is hydrogen, lower alkyl of 1 through 3 carbon atoms, fluorine, chlorine, bromine, nitro, trifluoromethyl or lower alkylthio of 1 through 3 carbon atoms, and the pharmacologically acceptable acid addition salts thereof, in association with a pharmaceutical carrier. The process is the administration of the above compositions to humans or animals at a dose of from about 0.01 mg./kg./day to about 2 mg./kg./day for anti-anxiety or anti-depressant effects.

Abstract: A process for the production of known compounds of the formula IV ##SPC1##wherein R.sub.1 is hydrogen or alkyl of 1 to 3 carbon atoms, inclusive; wherein R.sub.2 is hydrogen, chloro, or fluoro; wherein R.sub.3 is hydrogen, or fluoro with the proviso that R.sub.3 is not fluoro if R.sub.2 is chloro; wherein R.sub.4 is hydrogen, chloro, fluoro, bromo, nitro, and trifluoromethyl, which comprises: treating a compound of the formula I: ##SPC2##wherein R.sub.1, R.sub.2, R.sub.3, and R.sub.4 have the same significance as above, in formic acid solution with aqueous formaldehyde; treating the resulting compound with phthalimide, triphenylphosphine and then diethyl azodicarboxylate to give a compound which when heated with hydrazine, gives compound IV above.The compounds of formula IV above are known useful antidepressant, tranquilizing, sedative and anti-convulsant agents. The intermediates have also activity in the sedative-tranquilizing area and these compounds can be used in mammals and birds for tranquilization.

Abstract: A process for the production of compounds of the formula III: ##SPC1##wherein ring A is unsubstituted or substituted by fluoro, chloro, bromo, trifluoromethyl, or nitro, and wherein Ar is phenyl, o-chlorophenyl, o-fluorophenyl, or 2-pyridyl, is claimed in which the starting compound is the corresponding 1-methyl-6-substituted-4H-s-triazolo[4,3-a][1,4]-benzodiazepine. Compound III is converted to compoud IV or V, the corresponding 1-(2-aminoethyl)-6-substituted-4H-s-triazolo[4,3-a][1,4]benzodiazepines, which are known antidepressant and anti-anxiety agents.

Abstract: A process to make 6-phenyl-4H-s-triazolo[4,3-a][1,4]-benzodiazepines by converting 2-[3-(hydroxymethyl)-4H-1,2,4-triazol-4-yl]benzophenones to 2-[3-[(phthalimido or methanesulfonyl)methyl]-4H-1,2,4-triazol-4-yl]benzophenones and converting these compounds to the highly active 6-phenyl-4H-s-triazolo[4,3-a][1,4]benzodiazepines useful as tranquilizers and sedatives.

Abstract: Preparing 1-halo-6-phenyl-4H-s-triazolo[4,3-a][1,4]benzodiazepines by reacting an N-halosuccinimide with a 2-[3-(phthalimidomethyl)triazolyl]benzophenone to form the 2-[5-halo-3-(phthalimidomethyl)triazolyl] benzophenone and reacting the 2-[5-halo-3-(phthalimidomethyl)triazol-4-yl]benzophenone with hydrazine or a primary amine in an organic liquid solvent medium at 25.degree. to 100.degree. C. The products of the process have CNS tranquilizer and sedative properties but are also of interest for use as intermediates to prepare 2,4-dihydro-6-phenyl-1H-s-triazolo[4,3-a] [1,4]benzodiazepin-1-ones which are of clinical interest for their CNS tranquilizer, sedative and anti-depressant drug use properties in mammalian animals including humans.

Abstract: 6-Phenyl-4H-s-triazolo[4,3-a][1,4]benzodiazepines of the formula (IV): ##SPC1##wherein R is selected from the group consisting of hydrogen, alkyl of 1 to 3 carbon atoms, inclusive, phenyl, benzyl and -COOR' in which R' is alkyl of 1 to 4 carbon atoms, inclusive; wherein R.sub.1 is selected from the group consisting of hydrogen and alkyl of 1 to 3 carbon atoms, inclusive; and wherein R.sub.2, R.sub.3, R.sub.4 and R.sub.5 are selected from the group consisting of hydrogen, alkyl of 1 to 3 carbon atoms, inclusive, halogen, nitro, cyano, trifluoromethyl, and alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkanoylamino and dialkylamino in which the carbon chain moieties are of 1 to 3 carbon atoms, inclusive, are produced by condensing a 1,3-dihydro-5-phenyl-2H-1,4-benzodiazepine-2-thione of the formula (I): ##SPC2## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 are defined as above, with an organic acid hydrazide of the formula: ##EQU1## wherein R is defined as above.

Abstract: Therapeutic compositions for treating humans and animals comprising, in dosage unit form, a 8-Chloro-1-methyl-6-phenyl-4H-s-triazolo[4,3-a][1,4]benzodiazepine compound of the formula ##SPC1##Including the N-oxides and pharmacologically acceptable acid addition salts thereof in combination with a pharmaceutical carrier. The compositions are useful as soporifics and provide a process for inducing sleep.

Abstract: Therapeutic compositions for treating humans and animals comprising, in dosage unit form, a 8-chloro-1-methyl-6-(o-chlorophenyl)-4H-s-triazolo[4,3-a][1,4]benzodiazepi ne compound of the formula ##SPC1##Including the N-oxides and pharmacologically acceptable acid addition salts thereof in combination with a pharmaceutical carrier. The compositions are useful as soporifics and provide a process for inducing sleep.

Abstract: Pharmaceutical compositions comprising, in unit dosage form, from about 0.5 mg. to about 100 mg. of a compound of the formula: ##SPC1##Wherein R, R.sub.1, R.sub.2 and R.sub.3 are hydrogen, methyl or ethyl, and R.sub.4 is hydrogen, fluorine, chlorine, bromine, --NO.sub.2, --CF.sub.3, or methylthio, inclusive; including the pharmacologically acceptable acid addition salts thereof, in association with a pharmaceutical carrier. The process is the administration of the above compositions to humans at a dose of from about 0.1 mg./kg./day to about 10 mg./kg./day for anti-depressant therapy with minimum sedative side-effects.

Abstract: Pharmaceutical compositions comprising, in unit dosage form, from about 0.5 mg. to about 100 mg. of a compound of the formula: ##SPC1##Where R, R.sub. 1, R.sub.2 and R.sub.3 is hydrogen, methyl or ethyl, and R.sub.4 is hydrogen, fluorine, chlorine, bromine, --NO.sub.2, --CF.sub.3, or methylthio, inclusive; including the pharmacologically acceptable acid addition salts thereof, in association with a pharmaceutical carrier. The process is the administration of the above compositions to humans at a dose of from about 0.1 mg./kg./day to about 10 mg./kg./day for antidepressant therapy with minimal sedative side effects.

Abstract: A multistep process for the production of a compound of the formula V: ##SPC1##wherein R' and R" are alkyl of 1 to 3 carbon atoms, inclusive or together ##EQU1## is pyrrolidino, piperidino, 4-methylpiperazino or morpholino; and wherein the rings A and B are unsubstituted, or substituted by one or more substituents selected from the group consisting of fluoro, chloro, bromo, nitro and trifluoromethyl, which comprises treating an equivalent of a compound of formula 1: ##SPC2##Wherein rings A and B are defined as above, with 2 equivalents of an .alpha.